Pancreatic Cancer News Perioperative adaptive dynamic therapy can improve overall survival in patients with localized pancreatic cancer, new research suggests.
Sequential nab-P/Gem-mFOLFOX improved overall survival, progression-free survival, and time to progression.
Post-induction chemoradiotherapy improved resectability, vs chemotherapy alone, in unresectable, locally advanced pancreatic cancer.
Adding nab-paclitaxel to gemcitabine did not appear to improve survival in a real-world cohort.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of von Hippel-Lindau disease.
Patients with pancreatic cancer were 3 times more likely to have gallstone disease in the year prior to their cancer diagnosis, when compared with non-cancer patients.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Zollinger-Ellison syndrome.
A team of investigators examined the potential of fecal and salivary microbiota to serve as diagnostic biomarkers for pancreatic ductal adenocarcinoma.
The model uses features in CT scans of the abdomen to help identify patients at high risk of developing pancreatic ductal adenocarcinoma.
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
The incidence of pancreatic neuroendocrine tumors is increasing in the United States, but overall survival for these patients is improving.
AI models could enable earlier detection of pancreatic cancer and improve treatment options for patients, according to researchers.
Black patients are disproportionately excluded from participation in pancreatic cancer clinical trials.
Researchers discovered actionable germline genetic variants in 20% of patients who did not meet genetic testing criteria according to prior guidelines.
Fecal metagenomics classifiers proved better than salivary-based classifiers for identifying pancreatic ductal adenocarcinoma.
The mortality risk was lower for patients exposed to ACE inhibitors in first 3 years after pancreatic cancer diagnosis.
Sotorasib exhibited antitumor activity in a phase 1/2 trial of pretreated patients with KRAS G12C-mutated, advanced pancreatic cancer.
A model using routine clinical information can predict pancreatic ductal adenocarcinoma after diagnosis of impaired fasting glucose.
In addition to improved overall survival, patients in the neoadjuvant arm had longer disease-free survival and locoregional failure-free intervals.
In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.
Load More